T1	Condition 46 51	NSCLC
T2	Qualifier 25 37	PD-L1 status
R1	Has_qualifier Arg1:T1 Arg2:T2	
T3	Procedure 53 59	Biopsy
T4	Temporal 68 101	within 70 days of first treatment
T5	Reference_point 86 120	first treatment with pembrolizumab
T6	Drug 107 120	pembrolizumab
R2	Has_temporal Arg1:T3 Arg2:T4	
R3	Has_index Arg1:T4 Arg2:T5	
T7	Measurement 123 146	ECOG performance status
T8	Value 147 148	2
R4	Has_value Arg1:T7 Arg2:T8	
T9	Observation 151 166	Life expectancy
T10	Measurement 230 289	Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
T11	Value 180 208	Uni-dimensionally measurable
T12	Condition 209 216	disease
T13	Context_Error 209 216	disease
R5	AND Arg1:T12 Arg2:T10	
R6	Has_value Arg1:T10 Arg2:T11	
T14	Procedure 291 345	Computerised Tomography (CT) scan of chest and abdomen
T15	Temporal 346 386	within 28 days of starting pembrolizumab
T16	Reference_point 364 386	starting pembrolizumab
T17	Drug 373 386	pembrolizumab
R7	Has_index Arg1:T15 Arg2:T16	
R8	Has_temporal Arg1:T14 Arg2:T15	
T18	Measurement 424 438	Platelet count
T19	Value 439 452	≥100 x 109 /L
R9	Has_value Arg1:T18 Arg2:T19	
T20	Measurement 455 466	Neutrophils
T21	Value 467 479	≥1.5 x 109/L
R10	Has_value Arg1:T20 Arg2:T21	
T22	Measurement 482 493	Haemoglobin
T23	Value 494 501	≥ 9g/dL
R11	Has_value Arg1:T22 Arg2:T23	
T24	Parsing_Error 389 422	Adequate haematological function:
T25	Parsing_Error 504 530	Adequate hepatic function:
T26	Measurement 532 547	Serum bilirubin
T27	Value 548 582	≤1.5 x upper limit of normal (ULN)
R12	Has_value Arg1:T26 Arg2:T27	
T28	Measurement 585 604	Serum transaminases
T29	Value 605 615	≤2.5 x ULN
R13	Has_value Arg1:T28 Arg2:T29	
T30	Measurement 643 663	Creatinine clearance
T31	Value 664 678	<1.5 times ULN
R14	Has_value Arg1:T30 Arg2:T31	
T32	Temporal 679 689	concurrent
T33	Measurement 695 715	creatinine clearance
T34	Value 716 726	>50 ml/min
R15	Has_value Arg1:T33 Arg2:T34	
R16	Has_temporal Arg1:T30 Arg2:T32	
R17	Has_temporal Arg1:T33 Arg2:T32	
T35	Measurement 627 641	renal function
T36	Value 618 626	Adequate
R18	Has_value Arg1:T35 Arg2:T36	
T37	Scope 643 726	Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min
R19	Subsumes Arg1:T36 Arg2:T37	
T38	Post-eligibility 729 847	Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
T39	Non-query-able 729 847	Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
